Levi & Korsinsky, LLP announces that a VRCA class action lawsuit has been filed on behalf of investors who purchased Verrica Pharmaceuticals, Inc. (VRCA) securities between May 28, 2021, and May 24, 2022. For more on the VRCA Lawsuit please contact us today.

According to the Verricalawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(1) there were manufacturing deficiencies at the facility where Verrica’s contract manufacturer produced a bulk solution for the Company’s lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

TO LEARN MORE ABOUT THE VRCA CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Verrica you have until August 5, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com